Pharma Industry News

Promega Corp. v. Life Technologies Corp. (Fed. Cir. 2017)

By Donald Zuhn –- At about this time last year, the Supreme Court reversed the Federal Circuit's determination that there are circumstances in which a party may be liable for infringement under 35 U.S.C. § 271(f)(1) for supplying or causing to be supplied a single component of a patented combination outside the United States (see "Life Technologies Corp. v. Promega Corp. (2017)"). This past November, the dispute between Promega Corp. and Life Technologies Corp. returned to the Federal Circuit on remand, with the Federal Circuit affirming the District Court's grant of judgment as a matter of law (JMOL) to Life…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]